« Return to News | CROs/Service Providers

Ecron Acunova acquires majority stake in aCROnordic

Tuesday, March 29, 2011 01:15 PM

Ecron Acunova, a CRO based in Bangalore, India, has acquired a majority stake in aCROnordic, a CRO operating across the Nordic region, according to PharmaTimes.

Ecron has corporate offices Princeton, N.J., and in Frankfurt, Germany, and has operations in 19 Western and Eastern European countries as well as seven markets across South and South East Asia.

aCROnordic provides CRO services to the pharmaceutical and medical device industries, focusing on neurology, oncology and cardiology. Its headquarters are in Scion-DTU near Copenhagen, the largest university science park in Denmark, and its field of operations covers Denmark, Sweden, Finland and Norway.

D.A. Prasanna, founder and chairman of Ecron Acunova, said the recent shift toward strategic outsourcing in clinical research called for a “more global presence of preferred provider CROs.”

According to Søren Strøh, CEO of aCROnordic, the merger is “an opportunity to fulfill our dream of being the first Nordic development CRO in an international organization.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.